A COMPARATIVE ANALYSIS OF TWO DIFFERENT SAMPLES OF SIDDHA CLASSICAL FORMULATION-PADIGALINGA CHENDURAM

Siddha is the traditional system of medicine in India which is practiced in southern part. This traditional system has many polyherbal and herbo-mineral formulation which is more effective but they lack standardization procedures. Standardization of a herbo- mineral formulation is essential to assess the quality, efficacy, purity and safety of the drug. The present paper deals with standardization of Padigalinga Chenduram, the Siddha formulation which is used for treating menorrhagia, diarrhoea, dysentry etc. In-house preparation and one marketed sample were subjected to standardization techniques like organoleptic study, physicochemical screening and heavy metal analysis. It was observed that both the samples differ in their organoleptic character, physicochemical analysis and heavy metal analysis like colour variance, percent weight loss on drying or moisture content was found to be less in market sample and total ash value was high as well. And the market sample was found to be better than the in-house sample in water-soluble and alcohol-soluble extractive values. The toxic heavy metals as per AAS is found in both formulations and the values are not matching with each other, and it may be due to the raw material collection time and geographical variation, etc. which can be further investigated for its pharmacological activity. More number of samples from different pharmas has to be studied to arrive at definite standard for manufacturing Padigalinga Chenduram. When a definite standard is arrived from future studies, Padigalinga Chenduram will be a cost effective Siddha formulation for the treatment of various ailments

ERICA: Enabling real-time mistake detection and corrective feedback for free-weights exercises

National Research Foundation (NRF) Singapore under International Research Centres in Singapore Funding Initiativ

GameOn: P2p gaming on public transport

Ministry of Education, Singapore under its Academic Research Funding Tier

Smartphones and BLE services: Empirical insights

Ministry of Education, Singapore under its Academic Research Funding Tier 2; National Research Foundation (NRF) Singapore under IDM Futures Funding Initiativ

LiveLabs: Building in-situ mobile sensing and behavioural experimentation testbeds

© 2016 ACM. In this paper, we present LiveLabs, a first-of-its-kind testbed that is deployed across a university campus, convention centre, and resort island and collects real-time attributes such as location, group context etc., from hundreds of opt-in participants. These venues, data, and participants are then made available for running rich humancentric behavioural experiments that could test new mobile sensing infrastructure, applications, analytics, or more social-science type hypotheses that influence and then observe actual user behaviour. We share case studies of how researchers from around the world have and are using LiveLabs, and our experiences and lessons learned from building, maintaining, and expanding Live- Labs over the last three years.Y

The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma

There is a paucity of granular data on infection risk with B-cell maturation antigen (BMCA) and GPRC5D bispecific antibodies (bsAb) in relapsed/refractory multiple myeloma (RRMM). The aim of our multi-institutional study was to characterize the incidence, etiologies, and risk factors of infections from the start of therapy to the last follow-up or 90 days after study exit. A total of 66 patients received BCMA bsAb monotherapy, 15 GPRC5D bsAb monotherapy, and 15 GPRC5D bsAb combination therapy with daratumumab and/or pomalidomide. While the infection rate per 100 days was 0.57 for BCMA bsAb, it was 0.62 for GPRC5D bsAb combination and 0.13 for GPRC5D bsAb monotherapy; P=0.05. The proportion of infections that were grade ≥3 was higher in the BCMA bsAb group compared to the GPRC5D groups (58% vs. 36%; P=0.04). Grade 5 events were observed in 8% (n=8) of the patients, all treated with BCMA bsAb. The 9 month cumulative incidence of any grade of infection was similar in the BCMA and GPRC5D-combination groups (57% and 62%) and significantly higher than in the GPRC5D-mono group (16%); P=0.012. The cumulative incidence of grade ≥3 infections was highest in the BCMA group reaching 54% at 18 months; P=0.06. Multivariate analysis showed that BCMA bsAb therapy or GPRC5D combination therapy, history of previous infections, baseline lymphopenia, and baseline hypogammaglobulinemia were significantly associated with a higher risk of grade ≥3 infections. Our results indicate that BCMA bsAb and GPRC5D-combination therapies in RRMM are associated with higher cumulative incidence of infection and grade ≥3 infection compared to GPRC5D bsAb mono

Measurement of χ c1 and χ c2 production with s√ = 7 TeV pp collisions at ATLAS

The prompt and non-prompt production cross-sections for the χ c1 and χ c2 charmonium states are measured in pp collisions at s√ = 7 TeV with the ATLAS detector at the LHC using 4.5 fb−1 of integrated luminosity. The χ c states are reconstructed through the radiative decay χ c → J/ψγ (with J/ψ → μ + μ −) where photons are reconstructed from γ → e + e − conversions. The production rate of the χ c2 state relative to the χ c1 state is measured for prompt and non-prompt χ c as a function of J/ψ transverse momentum. The prompt χ c cross-sections are combined with existing measurements of prompt J/ψ production to derive the fraction of prompt J/ψ produced in feed-down from χ c decays. The fractions of χ c1 and χ c2 produced in b-hadron decays are also measured

Measurement of the production of a W boson in association with a charm quark in pp collisions at √s = 7 TeV with the ATLAS detector

The production of a W boson in association with a single charm quark is studied using 4.6 fb−1 of pp collision data at s√ = 7 TeV collected with the ATLAS detector at the Large Hadron Collider. In events in which a W boson decays to an electron or muon, the charm quark is tagged either by its semileptonic decay to a muon or by the presence of a charmed meson. The integrated and differential cross sections as a function of the pseudorapidity of the lepton from the W-boson decay are measured. Results are compared to the predictions of next-to-leading-order QCD calculations obtained from various parton distribution function parameterisations. The ratio of the strange-to-down sea-quark distributions is determined to be 0.96+0.26−0.30 at Q 2 = 1.9 GeV2, which supports the hypothesis of an SU(3)-symmetric composition of the light-quark sea. Additionally, the cross-section ratio σ(W + +c¯¯)/σ(W − + c) is compared to the predictions obtained using parton distribution function parameterisations with different assumptions about the s−s¯¯¯ quark asymmetry